Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Alteogen, 3SBio Agree Pact For ‘Biobetter’ Trastuzumab ADC

This article was originally published in PharmAsia News

Executive Summary

Chinese biotech 3SBio has licensed greater China rights to Alteogen’s novel trastuzumab-containing antibody-drug conjugate for breast cancer, in a deal that will expand 3SBio’s biologics pipeline and eventually provide competition in the indication to major firms including Roche.

Advertisement

Related Content

Should Pharma Be Concerned About Cooling China-Korea Ties?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register